September 11, 2012. Sonia Nagda, a Senior Fellow at NRC, testifies at a Pediatrics FDA Advisory Committee meeting on the use of drospirenone-containing oral contraceptive, Beyaz, in pediatric populations.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Testimony at FDA Advisory Committee Hearing on Metal-on-Metal Hip Implants
June 27, 2012. Metal-on-metal hip implants were approved by the FDA without requiring clinical studies before approval or following patients after their surgery for potential side effects. Now, 500,000 patients have metal-on-metal implants that have been widely reported to wear down and create metal debris inside patients’ bodies. Dr. Zuckerman testifies to the FDA about the lack of long-term clinical trials at their Advisory Committee hearing.
Read More »Comments to the CDC on Hepatitis C Virus Screening
June 6, 2012. NRC supports CDC’s expansion of guidelines for Hepatitis C screening for baby boomer adults.
Read More »Testimony to FDA Advisory Committee on Atrial Septal Defect Occluders
May 4, 2012. Sonia Nagda, a Senior Fellow at NRC, testifies at an FDA advisory committee meeting on the post-market studies of atrial septal defect occluders.
Read More »Comments on Sorbent Hemoperfusion Devices for the Treatment of Poisoning, Drug Overdose, Hepatic Coma, and Metabolic Disturbances
May 17, 2012. To ensure public health and patient safety, sorbent hemoperfusion devices for the treatment of poisoning, drug overdose, hepatic coma, and metabolic disturbances should remain class III devices and go through the more stringent PMA process, which requires clinical trials and inspections.
Read More »